The National Medical Products Administration in China approved lisaftoclax (APG-2575), a Bcl-2 selective inhibitor, for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who have previously received at least one systemic therapy including Bruton’s tyrosine kinase (BTK) inhibitors.
The European Medicines Agency’s Committee for Medicinal Products for Human Use adopted positive opinions, recommending the granting of marketing authorizations, for two biosimilar medicines in oncology: Ascend’s Denosumab Ascend and Qilu’s Nylaspeg.
